Global prevalence of hidradenitis suppurativa and geographical variation—systematic review and meta-analysis
Tóm tắt
There is a significant variation in the reported prevalence of hidradenitis suppurativa (HS), ranging from 0.03–4%. We hypothesized that this significant variation may be due to different prevalence rates of HS according to geographical location as well as sex. We aimed to perform a meta-analysis to determine pooled overall prevalence of HS, prevalence stratified according to geographical region and sex. A systematic review was performed by searching Ovid Medline, PubMed, Cochrane Library, DARE, and Embase, from inception to August 2018. A systematic review and meta-analysis was performed according to PRISMA guidelines. A meta-analysis of proportions was performed to determined pooled prevalence rates, with meta-regression based on geographic region. Prevalence in males versus females was also performed according to region. The overall pooled prevalence rate was 0.3% (0.2–0.6%) based on 118,760,093 HS cases available. Subgroup analysis demonstrated prevalence differences, with the highest being in Europe 0.8% (0.5–1.3%), compared to the USA 0.2% (0.1–0.4%), Asia-Pacific 0.2% (0.01–2.2%), and South America 0.2% (0.01–0.9%). Prevalence in males was lower compared to females in the USA (OR 0.403, 95% CI 0.37–0.439, P < 0.001) as well as in Europe (OR 0.635, 95% CI 0.397–1.015, P = 0.08) but not in the Asia-Pacific region (OR 0.936, 95% CI 0.319–2.751, P = 0.78). Prevalence of HS varies significantly according to the geographical population. This variation is likely attributed to different ethnicity distributions amongst different continents. III
Tài liệu tham khảo
Alavi A, Anooshirvani N, Kim WB, Coutts P, Sibbald RG. Quality-of-life impairment in patients with hidradenitis suppurativa: a Canadian study. American J Clin Derm. 2015;16:61–5.
Calao M, Wilson JL, Spelman L, et al. Hidradenitis Suppurativa (HS) prevalence, demographics and management pathways in Australia: a population-based cross-sectional study. PloS one. 2018;13:e0200683.
Cosmatos I, Matcho A, Weinstein R, Montgomery MO, Stang P. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2013;68:412–9.
Delany E, Gormley G, Hughes R, et al. A cross-sectional epidemiological study of hidradenitis suppurativa in an Irish population (SHIP). J Eur Acad Dermatol Venereol. 2018;32:467–73.
Garg A, Kirby JS, Lavian J, Lin G, Strunk A. Sex-and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA dermatol. 2017;153:760–4.
Hwang K, Baik S. Distribution of hairs and sweat glands on the bodies of Korean adults: a morphometric study. Cells Tissues Organs. 1997;158:112–20.
Ianhez M, Schmitt JV, Miot HA. Prevalence of hidradenitis suppurativa in Brazil: a population survey. Int J Dermatol. 2018;57:618–20.
Ingram J, Jenkins-Jones S, Knipe D, Morgan C, Cannings-John R, Piguet V. Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa. Br J Dermatol. 2018;178:917–24.
Ingram JR. The genetics of hidradenitis suppurativa. Dermatol clinics. 2016;34:23–8.
Jemec GB. Hidradenitis suppurativa. N Engl J Med. 2012;366:158–64.
Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol. 1996;35:191–4.
Jemec GB, Kimball AB. Hidradenitis suppurativa: epidemiology and scope of the problem. J Am Acad Dermatol. 2015;73:S4–7.
Kurokawa I, Hayashi N, Society JAR. Questionnaire surveillance of hidradenitis suppurativa in Japan. J Dermatol. 2015;42:747–9.
Lee JH, Kwon HS, Jung HM, Kim GM, Bae JM. Prevalence and comorbidities associated with hidradenitis suppurativa: a nationwide population-based study. J Eur Acad Dermatol Venereol. 2018;32:1784–90.
Liu M, Davis J, Idler K, Mostafa N, Okun M, Waring J. Genetic analysis of NCSTN for potential association with hidradenitis suppurativa in familial and nonfamilial patients. Br J Dermatol. 2016;175:414–6.
Lookingbill DP. Yield from a complete skin examination: findings in 1157 new dermatology patients. J Am Acad Dermatol. 1988;18:31–7.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9.
Reeder VJ, Mahan MG, Hamzavi IH. Ethnicity and hidradenitis suppurativa. J Invest Dermatol. 2014;134:2842.
Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59:596–601.
Richard MA, Corgibet F, Beylot-Barry M, et al. Sex-and age-adjusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the «OBJECTIFS PEAU» study. J Eur Acad Dermatol Venereol. 2018;32:1967–71.
Santos JV, Lisboa C, Lanna C, Costa-Pereira A, Freitas A. Is the prevalence of hidradenitis suppurativa being overestimated in Europe? Or is the disease underdiagnosed? Evidence from a nationwide study across Portuguese public hospitals. Int J Dermatol. 2017;56:1491–2.
Saunte DML, Jemec GBE. Hidradenitis suppurativa: advances in diagnosis and treatment. Jama. 2017;318:2019–32.
Schrader AM, Deckers IE, van der Zee HH, Boer J, Prens EP. Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity. J Am Acad Dermatol. 2014;71:460–7.
Shahi V, Alikhan A, Vazquez BG, Weaver AL, Davis MD. Prevalence of hidradenitis suppurativa: a population-based study in Olmsted County. Minnesota. Dermatology. 2014;229:154–8.
Sung S, Kimball AB. Counterpoint: analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2013;69:818–9.
Theut Riis P, Pedersen O, Sigsgaard V, et al. Prevalence of patients with self-reported hidradenitis suppurativa in a cohort of Danish blood donors: a cross-sectional study. Br J Dermatol. 2018;180:774–81.
Thomson M. A comparison between the number and distribution of functioning eccrine sweat glands in Europeans and Africans. J Physiol. 1954;123:225–33.
Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J. Dermatology QoLGotFSo. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol. 2007;56:621–3.
You HR, Yun SJ, Lee S-c, Won YH, Lee JB. Clinical characteristics and epidemiology of hidradenitis suppurativa in Korea: a single-center study. Korean J Dermatol. 2016;54:723–7.